Replies to post #48032 on Biotech Values

[poorgradstudent]

gnvc:

Bottom line, the CA19-9 data are not a positive for the drug. More like a non event.

What *is* disappointing is that the majority of the tumor response metrics (objective response, stable disease, progressive disease) were in favour of the standard of care arm. That makes it more likely that the extended median survival duration on the TNFerade arm may not be all that drug related.